Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals announced the results of its General Meeting, where a resolution to amend the company’s constitution to allow virtual-only meetings did not pass. Despite the setback, Paradigm clarified its commitment to maintaining shareholder rights in virtual meetings and emphasized the flexibility such amendments would provide during unforeseen circumstances. The company plans to continue holding hybrid Annual General Meetings to ensure both in-person and remote participation options for shareholders.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health and quality of life by developing pharmaceutical therapies. The company is currently working on iPPS for treating diseases where inflammation is a major factor, such as osteoarthritis and mucopolysaccharidosis.
Average Trading Volume: 979,262
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$118.8M
See more insights into PAR stock on TipRanks’ Stock Analysis page.